Cargando…
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
BACKGROUND: The current standard of care for pancreatic cancer is weekly gemcitabine administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum tolerated dose (MTD)-driven regimens as such are often associated with toxicities. Recent studies demonstrated that frequent dosing...
Autores principales: | Cham, K K Y, Baker, J H E, Takhar, K S, Flexman, J A, Wong, M Q, Owen, D A, Yung, A, Kozlowski, P, Reinsberg, S A, Chu, E M, Chang, C-W A, Buczkowski, A K, Chung, S W, Scudamore, C H, Minchinton, A I, Yapp, D T T, Ng, S S W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905290/ https://www.ncbi.nlm.nih.gov/pubmed/20531411 http://dx.doi.org/10.1038/sj.bjc.6605727 |
Ejemplares similares
-
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth
por: Yapp, Donald T., et al.
Publicado: (2016) -
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014) -
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008) -
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014) -
The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)